Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Ipsen Goes All In on Neuro with $1 Billion+ Deal For Exicure's Oligonucleotides
Ipsen Goes All In on Neuro with $1 Billion+ Deal For Exicure's Oligonucleotides
Ipsen, the global biopharmaceutical firm that specializes in neuroscience, oncology, and rare diseases, has partnered with Exicure, the clinical-stage biotech company that develops treatments for neur...
Full FDA Approval for COVID-19 Vaccine May Come in ‘Couple of Months,’ Report Says
Full FDA Approval for COVID-19 Vaccine May Come in ‘Couple of Months,’ Report Says
Full FDA approval for COVID-19 vaccines could come within the next couple of months, CNN reports.
GOP report on COVID-19 origins homes in on lab leak theory
GOP report on COVID-19 origins homes in on lab leak theory
A House Republican lawmaker’s investigation into the origins of COVID-19 is raising concerns that the pandemic outbreak stemmed from a genetically modified virus which leaked from the Wuhan Institut...
The curious case of Eohilia: Takeda drug hit with mysterious FDA delay as company leans on launches for growth
The curious case of Eohilia: Takeda drug hit with mysterious FDA delay as company leans on launches for growth
Takeda CEO Christophe Weber has been labeling 2021 as an “inflection year” for the Japanese pharma as it looks to advance its late-stage pipeline and introduce several new drugs.
CKD Drug Hit Phase III Endpoints Yet Rejected by FDA
CKD Drug Hit Phase III Endpoints Yet Rejected by FDA
Shares of Ardelyx Inc.
Eli Lilly and Kumquat Seek Enhanced Tumor-Specific Immune Response in $2B+ Deal
Eli Lilly and Kumquat Seek Enhanced Tumor-Specific Immune Response in $2B+ Deal
Loxo Oncology, a division of Eli Lilly, and Kumquat Biosciences are teaming up in a deal valued at more than $2 billion to discover and develop novel small molecules designed to stimulate tumor-specif...
Proof Covid is turning into a mild illness? Survivors who get reinfected have lower viral loads which make them less likely to become unwell or spread the virus
Proof Covid is turning into a mild illness? Survivors who get reinfected have lower viral loads which make them less likely to become unwell or spread the virus
Covid survivors who get reinfected have lower viral loads and are less likely to suffer symptoms, official data suggested today.
Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn) injection for the Treatment of Diabetes
Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn) injection for the Treatment of Diabetes
PITTSBURGH and BENGALURU, India, July 28, 2021 /PRNewswire/ -- Viatris Inc.
Self-Destructing Malaria-Spreading Mosquitos? How Genetic Engineering Could Make It So
Self-Destructing Malaria-Spreading Mosquitos? How Genetic Engineering Could Make It So
A breakthrough study has found that altering the genetic makeup of malaria-carrying mosquito species could be the key to stopping the spread of the malaria virus and finally eradicating the disease.
FDA alerts patients and health care professionals about clinical trial results showing an increased risk of death associated with Pepaxto (melphalan flufenamide)
FDA alerts patients and health care professionals about clinical trial results showing an increased risk of death associated with Pepaxto (melphalan flufenamide)
FDA is alerting patients and health care professionals that a clinical trial (OCEAN, Study OP-103) evaluating Pepaxto (melphalan flufenamide) with dexamethasone to treat patients with ...
U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir
U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir
(Reuters) - The U.
$2.5B Teneobio Deal Complements Amgen's Core and Capabilities
$2.5B Teneobio Deal Complements Amgen's Core and Capabilities
Amgen is snapping up privately-held TeneoBio and its class of biologics dubbed Human Heavy-Chain Antibodies in a deal that could total $2.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand